{"product_id":"mca-scientific-events-4th-congress-on-congenital-cytomegalovirus-2025","title":"MCA Scientific Events 4th Congress on Congenital Cytomegalovirus 2025","description":"\u003ch1\u003eMCA Scientific Events – 4th Congress on Congenital Cytomegalovirus (cCMV) 2025 (Videos)\u003c\/h1\u003e\r\n\u003ch2\u003eComprehensive Updates in Congenital Cytomegalovirus, Maternal-Fetal Infection, Prenatal Diagnosis, Neonatal Care, Antiviral Therapy, and Vaccine Development\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eStay at the forefront of congenital infection management with the \u003cstrong\u003eMCA Scientific Events – 4th Congress on Congenital Cytomegalovirus (cCMV) 2025\u003c\/strong\u003e, an advanced international continuing medical education (CME) program dedicated to the prevention, diagnosis, treatment, and long-term management of congenital cytomegalovirus (cCMV). Bringing together world-renowned experts in maternal-fetal medicine, neonatology, pediatric infectious diseases, virology, and immunology, this comprehensive congress provides the latest scientific evidence and practical clinical guidance covering the entire spectrum of congenital CMV—from pregnancy through infancy.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eHeld \u003cstrong\u003eNovember 20–21, 2025\u003c\/strong\u003e, in \u003cstrong\u003eNaples, Italy\u003c\/strong\u003e, with both \u003cstrong\u003ein-person and online participation\u003c\/strong\u003e, the congress is led by internationally recognized experts \u003cstrong\u003eProf. Yves Ville (France), Prof. Efraim Bilavsky (Israel), and Prof. Francesco Raimondi (Italy)\u003c\/strong\u003e. Through expert lectures, multidisciplinary discussions, clinical case reviews, and evidence-based presentations, participants gain practical insight into maternal screening, prenatal diagnosis, fetal imaging, antiviral therapies, neonatal management, hearing preservation, neurological outcomes, and future vaccine development.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eDesigned for clinicians and researchers involved in maternal, fetal, and pediatric healthcare, this program emphasizes multidisciplinary collaboration and precision medicine approaches to improve outcomes for infants affected by congenital CMV.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eProduct Details\u003c\/h1\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eCourse:\u003c\/strong\u003e 4th Congress on Congenital Cytomegalovirus (cCMV) 2025\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eProvider:\u003c\/strong\u003e MCA Scientific Events\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eConference Dates:\u003c\/strong\u003e November 20–21, 2025\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLocation:\u003c\/strong\u003e Naples, Italy (Hybrid: In-Person \u0026amp; Online)\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Videos\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eLanguage:\u003c\/strong\u003e English\u003c\/li\u003e\r\n \t\u003cli\u003e\n\u003cstrong\u003eEducational Level:\u003c\/strong\u003e Advanced\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eCourse Overview\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eCongenital cytomegalovirus remains the most common congenital viral infection worldwide and is a leading cause of sensorineural hearing loss, neurodevelopmental impairment, and long-term childhood disability. Advances in prenatal diagnosis, fetal imaging, molecular diagnostics, antiviral therapy, and neonatal screening continue to reshape clinical management and improve patient outcomes.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThe \u003cstrong\u003e4th Congress on Congenital Cytomegalovirus 2025\u003c\/strong\u003e provides a comprehensive review of current evidence and emerging innovations in cCMV care. International faculty discuss maternal screening strategies, serologic testing, fetal assessment, non-invasive prenatal testing, digital PCR, ultrasound, fetal MRI, antiviral therapy during pregnancy, neonatal treatment, hearing preservation, neurodevelopmental outcomes, and ongoing vaccine research.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eParticipants gain practical, evidence-based knowledge that can be directly applied to maternal-fetal medicine, neonatal care, pediatric infectious disease practice, and multidisciplinary congenital infection programs.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eWhat You'll Learn\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eAfter completing this course, participants will be able to:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eApply current international recommendations for CMV screening during pregnancy.\u003c\/li\u003e\r\n \t\u003cli\u003eInterpret maternal serologic testing for primary and non-primary CMV infection.\u003c\/li\u003e\r\n \t\u003cli\u003eUtilize prenatal diagnostic tools, including invasive testing and digital PCR.\u003c\/li\u003e\r\n \t\u003cli\u003eIntegrate ultrasound and fetal MRI findings into prenatal CMV assessment.\u003c\/li\u003e\r\n \t\u003cli\u003eOptimize antiviral treatment strategies during pregnancy and infancy.\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize the long-term neurological and auditory complications of congenital CMV.\u003c\/li\u003e\r\n \t\u003cli\u003eEvaluate hearing loss progression and treatment options in affected children.\u003c\/li\u003e\r\n \t\u003cli\u003eUnderstand current research on CMV vaccine development and future preventive strategies.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eComprehensive Topics Covered\u003c\/h1\u003e\r\n\u003ch2\u003eCongenital Cytomegalovirus (cCMV)\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eReview the epidemiology, virology, transmission, and clinical impact of congenital CMV infection across pregnancy, fetal life, and early childhood.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCongenital CMV infection\u003c\/li\u003e\r\n \t\u003cli\u003eMaternal infection\u003c\/li\u003e\r\n \t\u003cli\u003eVertical transmission\u003c\/li\u003e\r\n \t\u003cli\u003eFetal infection\u003c\/li\u003e\r\n \t\u003cli\u003eNeonatal CMV\u003c\/li\u003e\r\n \t\u003cli\u003eClinical manifestations\u003c\/li\u003e\r\n \t\u003cli\u003eLong-term follow-up\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eMaternal Screening \u0026amp; Diagnosis\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eDevelop a practical understanding of screening strategies and laboratory evaluation for CMV during pregnancy.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eMaternal screening\u003c\/li\u003e\r\n \t\u003cli\u003eSerologic testing\u003c\/li\u003e\r\n \t\u003cli\u003ePrimary infection\u003c\/li\u003e\r\n \t\u003cli\u003eNon-primary infection\u003c\/li\u003e\r\n \t\u003cli\u003eIgG avidity testing\u003c\/li\u003e\r\n \t\u003cli\u003eRisk assessment\u003c\/li\u003e\r\n \t\u003cli\u003eInternational screening practices\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eFaculty review the advantages and limitations of current screening approaches across different healthcare systems.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003ePrenatal Diagnosis\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eLearn modern diagnostic techniques for confirming fetal CMV infection.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eNon-invasive prenatal testing (NIPT)\u003c\/li\u003e\r\n \t\u003cli\u003eAmniocentesis\u003c\/li\u003e\r\n \t\u003cli\u003eDigital PCR\u003c\/li\u003e\r\n \t\u003cli\u003eMolecular diagnostics\u003c\/li\u003e\r\n \t\u003cli\u003ePrenatal laboratory testing\u003c\/li\u003e\r\n \t\u003cli\u003eDiagnostic algorithms\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eParticipants gain practical guidance on selecting appropriate diagnostic strategies based on gestational age and clinical presentation.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eFetal Imaging\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eStrengthen your ability to identify congenital CMV manifestations using advanced prenatal imaging.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eObstetric ultrasound\u003c\/li\u003e\r\n \t\u003cli\u003eFetal MRI\u003c\/li\u003e\r\n \t\u003cli\u003eBrain abnormalities\u003c\/li\u003e\r\n \t\u003cli\u003eGrowth assessment\u003c\/li\u003e\r\n \t\u003cli\u003eStructural anomalies\u003c\/li\u003e\r\n \t\u003cli\u003ePrognostic imaging\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eFaculty discuss imaging findings that influence prognosis and prenatal counseling.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eAntiviral Therapy\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eReview current evidence regarding antiviral treatment before and after birth.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eAntiviral medications\u003c\/li\u003e\r\n \t\u003cli\u003ePregnancy treatment\u003c\/li\u003e\r\n \t\u003cli\u003eNeonatal antiviral therapy\u003c\/li\u003e\r\n \t\u003cli\u003eTreatment indications\u003c\/li\u003e\r\n \t\u003cli\u003eDrug safety\u003c\/li\u003e\r\n \t\u003cli\u003eClinical outcomes\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eNeonatal \u0026amp; Pediatric Management\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eExplore multidisciplinary approaches to caring for infants with congenital CMV.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eNeonatal assessment\u003c\/li\u003e\r\n \t\u003cli\u003ePediatric follow-up\u003c\/li\u003e\r\n \t\u003cli\u003eDevelopmental surveillance\u003c\/li\u003e\r\n \t\u003cli\u003eMultidisciplinary care\u003c\/li\u003e\r\n \t\u003cli\u003eLong-term monitoring\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eHearing Loss \u0026amp; Neurodevelopment\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eUnderstand the major long-term complications associated with congenital CMV.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eSensorineural hearing loss\u003c\/li\u003e\r\n \t\u003cli\u003eAudiologic monitoring\u003c\/li\u003e\r\n \t\u003cli\u003eInner ear development\u003c\/li\u003e\r\n \t\u003cli\u003eNeurological disorders\u003c\/li\u003e\r\n \t\u003cli\u003eDevelopmental delay\u003c\/li\u003e\r\n \t\u003cli\u003eAutism spectrum research\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eFaculty discuss early detection, intervention, and long-term outcome optimization.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003eImmunology \u0026amp; Vaccine Development\u003c\/h2\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eReview the latest scientific advances in CMV immunology and vaccine research.\u003c\/p\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eTopics include:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eImmune response\u003c\/li\u003e\r\n \t\u003cli\u003eVaccine development\u003c\/li\u003e\r\n \t\u003cli\u003ePrevention strategies\u003c\/li\u003e\r\n \t\u003cli\u003eFuture therapies\u003c\/li\u003e\r\n \t\u003cli\u003eTranslational research\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eParticipants gain insight into one of the most promising areas of congenital infection prevention.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eLearning Objectives\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eUpon completion of this educational activity, participants will be able to:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eEvaluate maternal CMV screening strategies used internationally.\u003c\/li\u003e\r\n \t\u003cli\u003eInterpret serologic testing for primary and non-primary CMV infection.\u003c\/li\u003e\r\n \t\u003cli\u003eApply prenatal diagnostic tools, including invasive testing and digital PCR.\u003c\/li\u003e\r\n \t\u003cli\u003eIntegrate ultrasound and MRI findings into fetal prognosis.\u003c\/li\u003e\r\n \t\u003cli\u003eAssess antiviral treatment options during pregnancy and infancy.\u003c\/li\u003e\r\n \t\u003cli\u003eRecognize neurological and auditory complications associated with congenital CMV.\u003c\/li\u003e\r\n \t\u003cli\u003eMonitor hearing loss progression and evaluate therapeutic interventions.\u003c\/li\u003e\r\n \t\u003cli\u003eDiscuss advances in CMV vaccine development and future preventive strategies.\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eEducational Highlights\u003c\/h1\u003e\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eCongenital Cytomegalovirus (cCMV)\u003c\/li\u003e\r\n \t\u003cli\u003eMaternal-Fetal Medicine\u003c\/li\u003e\r\n \t\u003cli\u003ePrenatal Diagnosis\u003c\/li\u003e\r\n \t\u003cli\u003eMaternal Infection\u003c\/li\u003e\r\n \t\u003cli\u003eVertical Transmission\u003c\/li\u003e\r\n \t\u003cli\u003eNeonatal Medicine\u003c\/li\u003e\r\n \t\u003cli\u003ePediatric Infectious Diseases\u003c\/li\u003e\r\n \t\u003cli\u003eObstetric Ultrasound\u003c\/li\u003e\r\n \t\u003cli\u003eFetal MRI\u003c\/li\u003e\r\n \t\u003cli\u003eDigital PCR\u003c\/li\u003e\r\n \t\u003cli\u003eSerologic Testing\u003c\/li\u003e\r\n \t\u003cli\u003eAntiviral Therapy\u003c\/li\u003e\r\n \t\u003cli\u003eSensorineural Hearing Loss\u003c\/li\u003e\r\n \t\u003cli\u003eAudiology\u003c\/li\u003e\r\n \t\u003cli\u003eNeurodevelopment\u003c\/li\u003e\r\n \t\u003cli\u003eAutism Spectrum Research\u003c\/li\u003e\r\n \t\u003cli\u003eVirology\u003c\/li\u003e\r\n \t\u003cli\u003eVaccine Development\u003c\/li\u003e\r\n \t\u003cli\u003ePrecision Medicine\u003c\/li\u003e\r\n \t\u003cli\u003eContinuing Medical Education (CME)\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eWhy This Course Stands Out\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThe \u003cstrong\u003eMCA Scientific Events – 4th Congress on Congenital Cytomegalovirus 2025\u003c\/strong\u003e offers one of the most comprehensive educational programs dedicated exclusively to congenital CMV. Covering every stage from pregnancy through infancy, the congress combines cutting-edge research, international clinical guidelines, advanced prenatal diagnostics, fetal imaging, antiviral therapy, audiologic outcomes, and vaccine development into a practical, multidisciplinary curriculum. Its global faculty and evidence-based approach make it an invaluable resource for clinicians seeking to improve maternal, fetal, and neonatal outcomes in congenital CMV infection.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eTarget Audience\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eThis educational activity is ideal for:\u003c\/p\u003e\r\n\r\n\u003cul data-spread=\"false\"\u003e\r\n \t\u003cli\u003eObstetricians\u003c\/li\u003e\r\n \t\u003cli\u003eGynecologists\u003c\/li\u003e\r\n \t\u003cli\u003eMaternal-Fetal Medicine Specialists\u003c\/li\u003e\r\n \t\u003cli\u003ePediatricians\u003c\/li\u003e\r\n \t\u003cli\u003eNeonatologists\u003c\/li\u003e\r\n \t\u003cli\u003eInfectious Disease Specialists\u003c\/li\u003e\r\n \t\u003cli\u003ePediatric Infectious Disease Physicians\u003c\/li\u003e\r\n \t\u003cli\u003eVirologists\u003c\/li\u003e\r\n \t\u003cli\u003eAudiologists\u003c\/li\u003e\r\n \t\u003cli\u003eImmunologists\u003c\/li\u003e\r\n \t\u003cli\u003eFetal Medicine Specialists\u003c\/li\u003e\r\n \t\u003cli\u003eObstetrics \u0026amp; Gynecology Residents\u003c\/li\u003e\r\n \t\u003cli\u003eNeonatal Fellows\u003c\/li\u003e\r\n \t\u003cli\u003ePediatric Fellows\u003c\/li\u003e\r\n \t\u003cli\u003eHealthcare Professionals involved in maternal, fetal, and neonatal care\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch1\u003eWhy Choose This Course?\u003c\/h1\u003e\r\n\u003cp class=\"isSelectedEnd\"\u003eWhether you specialize in maternal-fetal medicine, neonatology, pediatrics, infectious diseases, or fetal imaging, the \u003cstrong\u003eMCA Scientific Events – 4th Congress on Congenital Cytomegalovirus 2025\u003c\/strong\u003e delivers an outstanding evidence-based review of congenital CMV. Featuring internationally recognized experts, multidisciplinary discussions, practical diagnostic strategies, advanced prenatal imaging, antiviral treatment updates, and emerging vaccine research, this program equips clinicians with the knowledge needed to optimize care from pregnancy through infancy.\u003c\/p\u003e\r\n\r\n\u003cdiv contenteditable=\"false\"\u003e\r\n\r\n\u003chr\u003e\r\n\r\n\u003c\/div\u003e\r\n\u003ch2\u003e\u003c\/h2\u003e\r\n\u003ch2 class=\"\" data-path-to-node=\"7\"\u003eTopics\u003c\/h2\u003e\r\n\u003cp data-path-to-node=\"8\"\u003e\u003cb class=\"\" data-path-to-node=\"8\" data-index-in-node=\"0\"\u003eThursday, 20 November 2025\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"9\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,0,0\"\u003e\u003cb class=\"\" data-path-to-node=\"9,0,0\" data-index-in-node=\"0\"\u003e09:00 – 09:10\u003c\/b\u003e\u003cspan class=\"\"\u003e | WELCOME FROM CONGRESS PRESIDENTS:\u003c\/span\u003e\u003cspan class=\"\"\u003e Yves Ville (France),\u003c\/span\u003e\u003cspan class=\"\"\u003e Francesco Raimondi (Italy),\u003c\/span\u003e\u003cspan class=\"\"\u003e Efraim Bilavsky (Israel)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,1,0\"\u003e\u003cb class=\"\" data-path-to-node=\"9,1,0\" data-index-in-node=\"0\"\u003e09:10 – 10:40 | SESSION 1 – SCREENING IN PREGNANCY\u003c\/b\u003e\u003cspan class=\"\"\u003e (Chairs:\u003c\/span\u003e\u003cspan class=\"\"\u003e Yves Ville,\u003c\/span\u003e\u003cspan class=\"\"\u003e France; Tiziana Lazzaroto,\u003c\/span\u003e\u003cspan class=\"\"\u003e Italy)\u003c\/span\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"9,1,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,1,1,0,0\"\u003e\u003cb class=\"\" data-path-to-node=\"9,1,1,0,0\" data-index-in-node=\"0\"\u003e09:10 – 09:40\u003c\/b\u003e\u003cspan class=\"\"\u003e | Screening in pregnancy,\u003c\/span\u003e\u003cspan class=\"\"\u003e in Italy and in France\u003c\/span\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"9,1,1,0,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,1,1,0,1,0,0\"\u003e\u003cspan class=\"\"\u003eOral Communication:\u003c\/span\u003e\u003cspan class=\"\"\u003e Outcome of primary CMV infection in pregnancy in Italy:\u003c\/span\u003e\u003cspan class=\"\"\u003e data from a large multicentric cohort before and after the introduction of valacyclovir in the clinical practice at country level (Lorenzo Zammarchi,\u003c\/span\u003e\u003cspan class=\"\"\u003e Italy)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,1,1,0,1,1,0\"\u003e\u003cspan class=\"\"\u003eOral Communication:\u003c\/span\u003e\u003cspan class=\"\"\u003e Congenital Cytomegalovirus Infection in Children Born to Mothers with Primary CMV Infection Treated with Valaciclovir:\u003c\/span\u003e\u003cspan class=\"\"\u003e Analysis of the Multi-center MEGAL-ITALI Study (Elisabetta Venturini,\u003c\/span\u003e\u003cspan class=\"\"\u003e Italy)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,1,1,0,1,2,0\"\u003e\u003cspan class=\"\"\u003eOral Communication:\u003c\/span\u003e\u003cspan class=\"\"\u003e Implementation of a national system for reporting and monitoring primary maternal CMV infections in France,\u003c\/span\u003e\u003cspan class=\"\"\u003e in response to the HAS recommendations (Sophie Alain,\u003c\/span\u003e\u003cspan class=\"\"\u003e France)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,1,1,1,0\"\u003e\u003cb class=\"\" data-path-to-node=\"9,1,1,1,0\" data-index-in-node=\"0\"\u003e09:40 – 10:00\u003c\/b\u003e\u003cspan class=\"\"\u003e | Serology made simple,\u003c\/span\u003e\u003cspan class=\"\"\u003e or nearly (Marianne Leruez Ville,\u003c\/span\u003e\u003cspan class=\"\"\u003e France)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,1,1,2,0\"\u003e\u003cb class=\"\" data-path-to-node=\"9,1,1,2,0\" data-index-in-node=\"0\"\u003e10:00 – 10:20\u003c\/b\u003e\u003cspan class=\"\"\u003e | How can we help pre-immune women?\u003c\/span\u003e\u003cspan class=\"\"\u003e (Daniele Lilleri,\u003c\/span\u003e\u003cspan class=\"\"\u003e Italy)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,1,1,3,0\"\u003e\u003cb class=\"\" data-path-to-node=\"9,1,1,3,0\" data-index-in-node=\"0\"\u003e10:20 – 10:40\u003c\/b\u003e\u003cspan class=\"\"\u003e | Discussion\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,2,0\"\u003e\u003cb class=\"\" data-path-to-node=\"9,2,0\" data-index-in-node=\"0\"\u003e10:40 – 11:20 | SESSION 2 – Oral communications\u003c\/b\u003e\u003cspan class=\"\"\u003e (Chairs:\u003c\/span\u003e\u003cspan class=\"\"\u003e Anna Gonce,\u003c\/span\u003e\u003cspan class=\"\"\u003e Spain; Christelle Vauloup-Fellous,\u003c\/span\u003e\u003cspan class=\"\"\u003e France)\u003c\/span\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"9,2,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,2,1,0,0\"\u003e\u003cspan class=\"\"\u003eOral Communication:\u003c\/span\u003e\u003cspan class=\"\"\u003e Occurrence of situations in which early CMV screening serology (\u0026lt;14 weeks of gestation) poses interpretative challenges (Christelle Vauloup-Fellous,\u003c\/span\u003e\u003cspan class=\"\"\u003e France)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,2,1,1,0\"\u003e\u003cspan class=\"\"\u003eOral Communication:\u003c\/span\u003e\u003cspan class=\"\"\u003e CMV-Scan:\u003c\/span\u003e\u003cspan class=\"\"\u003e a highly sensitive serological assay to detect maternal CMV non-primary infection (Ariane Larouche,\u003c\/span\u003e\u003cspan class=\"\"\u003e Canada)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,2,1,2,0\"\u003e\u003cspan class=\"\"\u003eOral Communication:\u003c\/span\u003e\u003cspan class=\"\"\u003e Reduction of voluntary termination of pregnancy in pregnant women with primary Cytomegalovirus infections treated with valaciclovir (Alice Bonetti,\u003c\/span\u003e\u003cspan class=\"\"\u003e Italy)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,2,1,3,0\"\u003e\u003cspan class=\"\"\u003eOral Communication:\u003c\/span\u003e\u003cspan class=\"\"\u003e Evolving Trends in Maternal Screening and First-Trimester Treatment:\u003c\/span\u003e\u003cspan class=\"\"\u003e Data from the French National Herpesvirus Reference Center (Elodie Ribot,\u003c\/span\u003e\u003cspan class=\"\"\u003e France)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,2,1,4,0\"\u003e\u003cspan class=\"\"\u003eOral Communication:\u003c\/span\u003e\u003cspan class=\"\"\u003e Beyond the Tip of the Iceberg:\u003c\/span\u003e\u003cspan class=\"\"\u003e The Clinical Impact of Maternal Non-Primary CMV Infection ICCG- Israel Congenital CMV Group (Goni Peleg,\u003c\/span\u003e\u003cspan class=\"\"\u003e Israel)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,3,0\"\u003e\u003cb class=\"\" data-path-to-node=\"9,3,0\" data-index-in-node=\"0\"\u003e11:30 – 12:00\u003c\/b\u003e\u003cspan class=\"\"\u003e | COFFEE BREAK\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,4,0\"\u003e\u003cb class=\"\" data-path-to-node=\"9,4,0\" data-index-in-node=\"0\"\u003e12:00 – 14:10 | SESSION 3 – PRENATAL DIAGNOSIS\u003c\/b\u003e\u003cspan class=\"\"\u003e (Chairs:\u003c\/span\u003e\u003cspan class=\"\"\u003e Valentine Faure-Bardon,\u003c\/span\u003e\u003cspan class=\"\"\u003e France; Marie-Luce Delforge,\u003c\/span\u003e\u003cspan class=\"\"\u003e Belgium)\u003c\/span\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"9,4,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,4,1,0,0\"\u003e\u003cspan class=\"\"\u003eNIPT for CMV in pregnancy (Brigitte Faas,\u003c\/span\u003e\u003cspan class=\"\"\u003e The Netherlands)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,4,1,1,0\"\u003e\u003cspan class=\"\"\u003eInvasive prenatal diagnosis (Nicolas Bourgon,\u003c\/span\u003e\u003cspan class=\"\"\u003e France)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,4,1,2,0\"\u003e\u003cspan class=\"\"\u003eIs there more for serology to say?\u003c\/span\u003e\u003cspan class=\"\"\u003e (Alfred Bissinger,\u003c\/span\u003e\u003cspan class=\"\"\u003e Germany (online))\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,4,1,3,0\"\u003e\u003cspan class=\"\"\u003eSecondary prevention,\u003c\/span\u003e\u003cspan class=\"\"\u003e an international registry (Christros Chatzakis,\u003c\/span\u003e\u003cspan class=\"\"\u003e United Kingdom)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,4,1,4,0\"\u003e\u003cb class=\"\" data-path-to-node=\"9,4,1,4,0\" data-index-in-node=\"0\"\u003e13:20 – 13:40\u003c\/b\u003e\u003cspan class=\"\"\u003e | Discussion\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,5,0\"\u003e\u003cb class=\"\" data-path-to-node=\"9,5,0\" data-index-in-node=\"0\"\u003e13:40 – 14:30\u003c\/b\u003e\u003cspan class=\"\"\u003e | LUNCH \/ POSTER VIEWING\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,6,0\"\u003e\u003cb class=\"\" data-path-to-node=\"9,6,0\" data-index-in-node=\"0\"\u003e14:30 – 15:20 | SESSION 4 – Oral Communications\u003c\/b\u003e\u003cspan class=\"\"\u003e (Chairs:\u003c\/span\u003e\u003cspan class=\"\"\u003e Jacques Fourgeaud,\u003c\/span\u003e\u003cspan class=\"\"\u003e France; Caroline De Coninck,\u003c\/span\u003e\u003cspan class=\"\"\u003e Belgium)\u003c\/span\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"9,6,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,6,1,0,0\"\u003e\u003cspan class=\"\"\u003eBeyond Real-Time PCR:\u003c\/span\u003e\u003cspan class=\"\"\u003e diagnostic accuracy of Digital PCR in the Pre-natal Diagnosis of Congenital CMV Infection (Liliana Gabrielli,\u003c\/span\u003e\u003cspan class=\"\"\u003e Italy)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,6,1,1,0\"\u003e\u003cspan class=\"\"\u003eHigh-Dose Valacyclovir in Primary Cytomegalovirus Infection During Pregnancy:\u003c\/span\u003e\u003cspan class=\"\"\u003e Effects on Immune Modulation and Maternal Serologic Response (Silvio Tartaglia,\u003c\/span\u003e\u003cspan class=\"\"\u003e Italy)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,6,1,2,0\"\u003e\u003cspan class=\"\"\u003eSuccessful prevention of fetal CMV infection by valacyclovir and the interval between maternal infection and treatment initiation,\u003c\/span\u003e\u003cspan class=\"\"\u003e a retrospective study (Jacob Amir,\u003c\/span\u003e\u003cspan class=\"\"\u003e Israel)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,6,1,3,0\"\u003e\u003cspan class=\"\"\u003eEvaluation of MyCMV:\u003c\/span\u003e\u003cspan class=\"\"\u003e A Tool to Enhance the Diagnosis of Cytomegalovirus Infection During Pregnancy (Jacques Fourgeaud,\u003c\/span\u003e\u003cspan class=\"\"\u003e France)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,6,1,4,0\"\u003e\u003cspan class=\"\"\u003eDiscussion\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,7,0\"\u003e\u003cb class=\"\" data-path-to-node=\"9,7,0\" data-index-in-node=\"0\"\u003e15:20 – 15:50\u003c\/b\u003e\u003cspan class=\"\"\u003e | COFFEE BREAK\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,8,0\"\u003e\u003cb class=\"\" data-path-to-node=\"9,8,0\" data-index-in-node=\"0\"\u003e15:50 – 17:20 | SESSION 5 – PROGNOSIS OF FETAL INFECTION\u003c\/b\u003e\u003cspan class=\"\"\u003e (Chairs:\u003c\/span\u003e\u003cspan class=\"\"\u003e Olivier Picone,\u003c\/span\u003e\u003cspan class=\"\"\u003e France; Francesco Raimondi,\u003c\/span\u003e\u003cspan class=\"\"\u003e Italy)\u003c\/span\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"9,8,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,8,1,0,0\"\u003e\u003cspan class=\"\"\u003eHow to combine ultrasound and MRI?\u003c\/span\u003e\u003cspan class=\"\"\u003e (Yves Ville,\u003c\/span\u003e\u003cspan class=\"\"\u003e France)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,8,1,1,0\"\u003e\u003cspan class=\"\"\u003eBiology of an infected fetus for best and for worse (Anna Gonce,\u003c\/span\u003e\u003cspan class=\"\"\u003e Spain)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,8,1,2,0\"\u003e\u003cspan class=\"\"\u003ePharmacology of antiviral drugs in pregnancy (Valentine Faure-Bardon,\u003c\/span\u003e\u003cspan class=\"\"\u003e France)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,8,1,3,0\"\u003e\u003cb class=\"\" data-path-to-node=\"9,8,1,3,0\" data-index-in-node=\"0\"\u003e16:50 – 17:20\u003c\/b\u003e\u003cspan class=\"\"\u003e | Discussion\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,9,0\"\u003e\u003cb class=\"\" data-path-to-node=\"9,9,0\" data-index-in-node=\"0\"\u003e17:20 – 18:10 | SESSION 6 – Oral communications\u003c\/b\u003e\u003cspan class=\"\"\u003e (Chairs:\u003c\/span\u003e\u003cspan class=\"\"\u003e Alfred Bissinger,\u003c\/span\u003e\u003cspan class=\"\"\u003e Germany (online); Hermione Lyall,\u003c\/span\u003e\u003cspan class=\"\"\u003e United Kingdom)\u003c\/span\u003e\u003c\/p\u003e\r\n\r\n\u003cul class=\"animating\" data-path-to-node=\"9,9,1\"\u003e\r\n \t\u003cli class=\"animating\"\u003e\r\n\u003cp class=\"animating\" data-path-to-node=\"9,9,1,0,0\"\u003e\u003cspan class=\"\"\u003eInhibitory effect of antivirals on CMV infection in human stem cell-derived neural systems (Renata Vieira De Sa,\u003c\/span\u003e\u003cspan class=\"\"\u003e The Netherlands)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli class=\"animating\"\u003e\r\n\u003cp class=\"animating\" data-path-to-node=\"9,9,1,1,0\"\u003e\u003cspan class=\"\"\u003eRate of post-amniocentesis transmission in pregnant women with primary cytomegalovirus infection treated with valaciclovir (Piera d’Angelo,\u003c\/span\u003e\u003cspan class=\"\"\u003e Italy)\u003c\/span\u003e\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,9,1,2,0\"\u003eCongenital cytomegalovirus causes increased expression of neutrophil granule genes and suppression of innate immune response genes (Helen Payne, United Kingdom)\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"9,9,1,3,0\"\u003e\u003cb data-path-to-node=\"9,9,1,3,0\" data-index-in-node=\"0\"\u003e18:00 – 18:10\u003c\/b\u003e | (Reserved block, unspecified details)\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003cp data-path-to-node=\"10\"\u003e\u003cb data-path-to-node=\"10\" data-index-in-node=\"0\"\u003eFriday, 21 November 2025\u003c\/b\u003e\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"11\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,0,0\"\u003e\u003cb data-path-to-node=\"11,0,0\" data-index-in-node=\"0\"\u003e09:00 – 11:00 | SESSION 7 – The present and future of children with congenital CMV\u003c\/b\u003e (Chairs: Ann Vossen, Belgium; Jacob Amir, Israel)\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"11,0,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,0,1,0,0\"\u003eImpact of CMV on the Inner Ear – Looking through the Developmental Lens (Sharon Cushing, Canada)\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,0,1,1,0\"\u003eRedefining the “Asymptomatic” Child in the Emerging Era of Universal cCMV Screening (Mark Schleiss, United States)\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,0,1,2,0\"\u003eThe link between cCMV and the autistic spectrum? (Marianne Leruez Ville \u0026amp; David Grévent, France)\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,0,1,3,0\"\u003eHow Close Are We? Prospects and Predicaments in Realizing the Goal of Licensing a Vaccine for Prevention of Congenital CMV (Mark Schleiss, United States)\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,0,1,4,0\"\u003eOral Communication: Beyond Hearing and Vision: Pilot Data on Olfactory Function in Congenital Cytomegalovirus (Serena Salomè, Italy)\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,0,1,5,0\"\u003eOral Communication: cCMV infection and risk of autism spectrum and other neurodevelopmental disorders in a large patient population in Northern California (Tara Greenhow, United States)\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,0,1,6,0\"\u003eOral Communication: \u003cspan class=\"citation-43 citation-end-43\"\u003eEducational attainment, absenteeism, and special educational needs outcomes in school children up to age 10\/11 with congenital cytomegalovirus (cCMV): A population-based cohort study using linked education and hospital data from Engla\u003c\/span\u003end (Ayana Cant, United Kingdom)\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,0,1,7,0\"\u003e\u003cb data-path-to-node=\"11,0,1,7,0\" data-index-in-node=\"0\"\u003e11:00 – 11:30\u003c\/b\u003e | Discussion\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,1,0\"\u003e\u003cb data-path-to-node=\"11,1,0\" data-index-in-node=\"0\"\u003e11:30 – 12:20\u003c\/b\u003e | COFFEE BREAK \u0026amp; POSTER WALK\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,2,0\"\u003e\u003cb data-path-to-node=\"11,2,0\" data-index-in-node=\"0\"\u003e12:20 – 13:30 | SESSION 8 – Hearing loss on children with congenial CMV\u003c\/b\u003e (Chairs: Anna Rita Fetoni, Italy; Efraim Bilavsky, Israel)\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"11,2,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,2,1,0,0\"\u003eCharacteristics of Progression in Hearing Loss in Children with cCMV (Sharon Cushing, Canada)\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,2,1,1,0\"\u003eAn Enzymatic Assay for Ganciclovir Triphosphate Monitoring in Infants With Congenital Cytomegalovirus (Willow Chernoske, United States)\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,2,1,2,0\"\u003eCMV-specific IFN-γ responses post QuantiFERON CMV test at birth correlate with symptoms at birth and long-term outcome in infants with congenital cytomegalovirus infection (Vana Papaevangelo, Greece)\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,2,1,3,0\"\u003e\u003cb data-path-to-node=\"11,2,1,3,0\" data-index-in-node=\"0\"\u003e13:00 – 13:30\u003c\/b\u003e | Discussion\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,3,0\"\u003e\u003cb data-path-to-node=\"11,3,0\" data-index-in-node=\"0\"\u003e13:30 – 14:30\u003c\/b\u003e | LUNCH AND POSTER VIEWING\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,4,0\"\u003e\u003cb data-path-to-node=\"11,4,0\" data-index-in-node=\"0\"\u003e14:30 – 15:00\u003c\/b\u003e | Debate on Antiviral treatment in children with late onset hearing loss\u003c\/p\u003e\r\n\r\n\u003cul data-path-to-node=\"11,4,1\"\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,4,1,0,0\"\u003ePRO – Efraim Bilavsky, Israel\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,4,1,1,0\"\u003eCONS – Ann Vossen, Belgium\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,5,0\"\u003e\u003cb data-path-to-node=\"11,5,0\" data-index-in-node=\"0\"\u003e15:00 – 15:15\u003c\/b\u003e | Discussion\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n \t\u003cli\u003e\r\n\u003cp data-path-to-node=\"11,6,0\"\u003e\u003cb data-path-to-node=\"11,6,0\" data-index-in-node=\"0\"\u003e15:15 – 15:30\u003c\/b\u003e | CLOSING REMARKS: Yves Ville (France), Francesco Raimondi (Italy), Efraim Bilavsky (Israel)\u003c\/p\u003e\r\n\u003c\/li\u003e\r\n\u003c\/ul\u003e","brand":"Meducourse","offers":[{"title":"Default Title","offer_id":43163708883042,"sku":"MED-AMB09616","price":40.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/MCA-Scientific-Events-4th-Congress-on-Congenital-Cytomegalovirus-2025.jpg?v=1785419454","url":"https:\/\/meducourse.com\/products\/mca-scientific-events-4th-congress-on-congenital-cytomegalovirus-2025","provider":"Meducourse","version":"1.0","type":"link"}